Expert Financial Analysis and Reporting

Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop an all oral combination treatment for hepatitis C […]

Investment Background Cadence Pharmaceuticals (CADX) achieved the goal of every emerging bio-pharmaceutical company when it received US approval for its first product Ofirmev on November 2, 2010; it was then launched on January 17, 2011. Ofirmev is an intravenous formulation of acetaminophen that was licensed from Bristol-Myers Squibb (BMY). It has been marketed in Europe […]

Investment Thesis The equity offering by A.P. Pharma of 102 million shares at $0.52 per share has put pressure on the stock, but it is gradually recovering and the current price of $0.58 presents a buying opportunity in my opinion. I initiated coverage with a buy at $0.42 per share on April 25, 2012. I […]

I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could be quite […]

The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that  in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma’s competitive […]

Cadence (CADX) has just released estimates from the independent market research firm Wolters, Kluwer on the number of vials that were shipped in April and May. The results are encouraging and suggest that Ofirmev could produce an upside sales surprise in upcoming second quarter. Management issued guidance after the first quarter for Ofirmev sales of […]

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as […]

I have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing with Surfaxin and Afectair and controls worldwide rights to these products with the exception of Surfaxin in Spain and Portugal. It also has a highly promising pipeline. Surfaxin LS is a meaningful improvement over Surfaxin […]

I have just published a report initiating coverage on A.P. Pharma (APPA, $0.42) in which I recommend purchase; my 2015 price target is $5.00+. The recommendation is keyed to the projected approval of APF530 for the treatment of chemotherapy induced nausea and vomiting in early 2013 and launch in the US in mid-2013. Most newly […]

Northwest Biotherapeutics’ (NWBO) DCVax-L and ImmunoCellular Therapeutics’ ICT-107 are dendritic cell cancer vaccines that are in phase II trials for the treatment of glioblastoma multiforme, the most malignant form of brain cancer. Their dendritic cell technology is the same as that used by Dendreon’s Provenge. Importantly, NWBO and IMUC both have much more efficient manufacturing […]